Solving the twin challenges of human and planetary health is the greatest task of our generation, and it also presents the greatest entrepreneurial opportunity in history, which is why we’ve partnered with Mayfield to bring you an engineering biology track to Disrupt 2021 this September 21-23. Haven’t secured your spot yet? Grab your ticket now […]
Imagine a future in which earbuds could harness the power of the brain to regulate immune function. Such is the ambition of NÄsos, a startup launching out of stealth today, following months of development. The team is pioneering a new method for the treatment of rheumatoid arthritis using neuroplasticity-altering electrical fields, delivered to the target brain areas via earbuds to help regulate immune function. The company is also announcing $16.5 million in funding led by Mayfield Fund and results from its pilot clinical trial.
A dysregulated immune function, resulting in chronic inflammation, is at the root of autoimmune disorders. Existing pharmaceutical treatments require systemic delivery, risking adverse side effects from broad immunosuppression. The potential to target a pathway that enables the brain to regulate immune function, using the brainâs electrical language, could provide a new treatment option without the side-effect profile of existing therapies.
Nesos raises funding for medical device to âhackâ the brain By Syndicated Content
By Manas Mishra
(Reuters) - San Francisco-based startup Nesos raised $16.5 million on Thursday to fund a medical device that it hopes can train parts of the brain to treat inflammatory diseases such as rheumatoid arthritis.
The company s experimental device, which resembles a pair of wireless earbuds, uses electric fields to make changes, or hack the brain, according to Nesos Chief Executive Officer Konstantinos Alataris.
The product could also be quicker to reach the market than treatments from the neuroscience startup of Tesla Inc s CEO Elon Musk, said Ursheet Parikh, a partner at Mayfield Fund, the venture capital firm which led the funding round.